IP Library Granted Patent US 11,685,905
Granted Patent B2
US 11,685,905 · App. 16/333,719 · Granted Jun 27, 2023

Rhamnolipid-producing cell having reduced glucose dehydrogenase activity

Inventors: Oliver Thum (Ratingen, DE); Steffen Schaffer (Herten, DE); Christoph Schorsch (Frankfurt am Main, DE); Mirja Wessel (Bochum, DE)
Assignee: Evonik Operations GmbH
C12N9/0006C12N15/52C12N15/78C12P19/44C12Y101/05002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,685,905
App. No.
16/333,719
Granted
Jun 27, 2023
Kind
B2
Abstract

The invention relates to cells which make rhamnolipids and are genetically modified such that they have a decreased activity, compared to the wild type thereof, of a glucose dehydrogenase and to a method for producing rhamnolipids using the cells according to the invention.

Claims (16)

1. A cell able to make at least one rhamnolipid a compound comprising general formula 1 , wherein the cell is P. putida KT2440 Aupp Agcd+pACYCATh5-{PrhaSR} [rhaSR_Ec] {rhaBAD} [rhlAB_Pa] {Talk} [araC_Ec] {ParaBAD} [rmlBDAC_Pa] {Talk}[D]], and wherein general formula (I) is

where

m=2, 1, or 0

n=1 or 0,

and R 1 is an organic radical having from 2 to 24 carbon atoms, and R 2 is is an organic radical having from 2 to 24 carbon atoms.

2. The cell according to claim 1 , wherein the rhamnolipid comprises a mixture of rhamnolipids comprising when n=1 in general formula (I) is more than 80% by weight of the rhamnolipids.

3. The cell according to claim 1 , wherein R 1 is an organic radical having from 5 to 13 carbon atoms, and R 2 is an organic radical having from 5 to 13 carbon atoms.

4. The cell according to claim 1 , wherein R 1 is selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH 2 ) o —CH 3 where o=1 to 23.

5. The cell according to claim 1 , wherein R 2 is selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH 2 ) o —CH 3 where o=1 to 23.

6. The cell according to claim 1 , wherein R 2 is selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl and tridecenyl and (CH 2 ) o —CH 3 where o=4 to 12.

7. The cell according to claim 1 , wherein R 1 and R 2 is

derived from 3-hydroxyoctanoyl-3-hydroxyoctanoic acid, 3-hydroxyoctanoyl-3-hydroxydecanoic acid, 3-hydroxydecanoyl-3-hydroxyoctanoic acid, 3-hydroxyoctanoyl-3-hydroxydecenoic acid, 3-hydroxydecenoyl-3-hydroxyoctanoic acid, 3-hydroxyoctanoyl-3-hydroxydodecanoic acid, 3-hydroxydodecanoyl-3-hydroxyoctanoic acid, 3-hydroxyoctanoyl-3-hydroxydodecenoic acid, 3-hydroxydodecenoyl-3-hydroxyoctanoic acid, 3-hydroxydecanoyl-3-hydroxydecanoic acid, 3-hydroxydecanoyl-3-hydroxydecenoic acid, 3-hydroxydecenoyl-3-hydroxydecanoic acid, 3-hydroxydecenoyl-3-hydroxydecenoic acid, 3-hydroxydecanoyl-3-hydroxydodecanoic acid, 3-hydroxydodecanoyl-3-hydroxydecanoic acid, 3-hydroxydecanoyl-3-hydroxydodecenoic acid, 3-hydroxydecanoyl-3-hydroxytetradecenoic acid, 3-hydroxytetradecanoyl-3-hydroxydecenoic acid, 3-hydroxydodecenoyl-3-hydroxydecanoic acid, 3-hydroxydecanoyl-3-hydroxytetradecanoic acid, 3-hydroxytetradecanoyl-3-hydroxydecanoic acid, 3-hydroxydecanoyl-3-hydroxytetradecenoic acid, 3-hydroxytetradecenoyl-3-hydroxydecanoic acid, 3-hydroxydodecanoyl-3-hydroxydodecanoic acid, 3-hydroxydodecenoyl-3-hydroxydodecanoic acid, 3-hydroxydodecanoyl-3-hydroxydodecenoic acid, 3-hydroxydodecanoyl-3-hydroxytetradecanoic acid, 3-hydroxytetradecanoyl-3-hydroxydodecanoic acid, 3-hydroxytetradecanoyl-3-hydroxytetradecanoic acid, 3-hydroxyhexadecanoyl-3-hydroxytetradecanoic acid, 3-hydroxytetradecanoyl-3-hydroxyhexadecanoic acid or 3-hydroxyhexadecanoyl-3-hydroxyhexadecanoic acid.

8. The method for producing rhamnolipids, comprising the method steps of

I) contacting the cell according to claim 1 , combining these measures as appropriate, with a medium containing a carbon source

II) culturing the cell under conditions allowing the cell to make rhamnolipid from the carbon source and

III) optionally isolating the rhamnolipids made.

Assignments (2)
CHANGE OF NAME Recorded Dec 27, 2019
From: EVONIK DEGUSSA GMBH
To: EVONIK OPERATIONS GMBH
Reel/Frame 051428/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: THUM, OLIVER; SCHAFFER, STEFFEN; SCHORSCH, CHRISTOPH; WESSEL, MIRJA
To: EVONIK DEGUSSA GMBH
Reel/Frame 048609/0111 →
Priority Claims (1)
EP 16195194 · Oct 24, 2016 · regional
Continuity (1)
Related Publication 20190271020A1 · Sep 5, 2019
Cited By (1)
US 12,448,588